Taysha Gene Therapies Inc (TSHA) Stock Price, Quote & News

Company Profile

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 214 612 0000

Website: www.tayshagtx.com

Address:

3000 Pegasus Park Drive, Suite 1430, Dallas, United States

stockmoe12 Jan. 17 at 2:18 AM

$TSHA I'm still expecting buyout announcement before data in Q3/4… let’s see ..

0 · Reply

Glide1 Jan. 16 at 7:25 PM

$TSHA does anybody know why this stock continues to slide. It had nothing but positive news but continues to be scalped. I am besides myself trying to figure it out.

2 · Reply

stockmoe12 Jan. 15 at 1:39 PM

$TSHA before ph3 data they want to tsie it out low price $OCUL .. tsha ph3 data coming q3/q4

0 · Reply

stockmoe12 Jan. 15 at 1:37 PM

$TSHA $OCUL buyout…..

0 · Reply

stockmoe12 Jan. 14 at 6:42 PM

$TSHA just looked into $NGNE safety data in the latest presentation .. looks like tsha is clear winner both in terms of safety and efficacy prospective.. lets see when is the buyout announcement coming!!!!!!! expecting like rgls

1 · Reply

stockmoe12 Jan. 14 at 4:49 PM

$TSHA slow and steady shorts are getting toasted ….need badly a short squeeze..

0 · Reply

stockmoe12 Jan. 14 at 1:44 AM

$TSHA can we get a short squeeze ..… finviz showing 25% shorts

0 · Reply

stockmoe12 Jan. 13 at 10:57 PM

$TSHA slowly moving and then blast …lets see

0 · Reply

Savon13 Jan. 12 at 2:01 AM

$TSHA https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation

1 · Reply

UgoGreg Jan. 10 at 4:11 PM

$TSHA https://youtu.be/ygBN8MilTyc

0 · Reply

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

Dec 5, 2025, 4:05 PM EST - 6 weeks ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 4, 2025, 2:36 PM EST - 2 months ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 2 months ago

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Oct 16, 2025, 4:01 PM EDT - 3 months ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

Oct 9, 2025, 8:00 AM EDT - 3 months ago

Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting

Oct 6, 2025, 10:07 AM EDT - 3 months ago

Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential

Oct 2, 2025, 8:00 AM EDT - 3 months ago

Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome

Aug 12, 2025, 1:38 PM EDT - 5 months ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:01 AM EDT - 5 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 5, 2025, 4:05 PM EDT - 5 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

Jun 3, 2025, 5:17 PM EDT - 8 months ago

Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program

May 29, 2025, 1:06 PM EDT - 8 months ago

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

May 28, 2025, 10:40 PM EDT - 8 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:02 PM EDT - 8 months ago

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 28, 2025, 4:01 PM EDT - 8 months ago

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

May 15, 2025, 2:07 PM EDT - 8 months ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:00 AM EDT - 8 months ago

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 4:05 PM EDT - 9 months ago

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15

Mar 31, 2025, 2:25 PM EDT - 10 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX NVAX SLDB SRPT XBI

Feb 26, 2025, 2:54 PM EST - 11 months ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:00 AM EST - 11 months ago

Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Feb 19, 2025, 8:00 AM EST - 11 months ago

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

Jan 27, 2025, 7:53 PM EST - 1 year ago

Taysha Gene Therapies Is Showing Promise For Rett Syndrome

Nov 14, 2024, 8:25 AM EST - 1 year ago

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

AAP

Nov 13, 2024, 10:48 PM EST - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 1 year ago

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress

Oct 14, 2024, 12:55 AM EDT - 1 year ago

Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data

Aug 12, 2024, 12:08 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 26, 2024, 7:36 AM EDT - 1 year ago

Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

GIS

Jun 18, 2024, 11:42 AM EDT - 1 year ago

What's Going On With Taysha Gene Therapies Stock Tuesday?

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

Jun 12, 2024, 7:00 AM EDT - 1 year ago

Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting

May 15, 2024, 4:55 AM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14

May 2, 2024, 8:00 AM EDT - 1 year ago

Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome

Mar 20, 2024, 12:30 PM EDT - 1 year ago

Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts

Mar 19, 2024, 9:04 PM EDT - 1 year ago

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Mar 14, 2024, 4:26 PM EDT - 2 years ago

Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19

Feb 29, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome

Feb 15, 2024, 4:01 PM EST - 2 years ago

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Jan 22, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Dec 19, 2023, 7:30 AM EST - 2 years ago

Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies

TRIN

Nov 29, 2023, 8:00 AM EST - 2 years ago

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients

stockmoe12 Jan. 17 at 2:18 AM

$TSHA I'm still expecting buyout announcement before data in Q3/4… let’s see ..

0 · Reply

Glide1 Jan. 16 at 7:25 PM

$TSHA does anybody know why this stock continues to slide. It had nothing but positive news but continues to be scalped. I am besides myself trying to figure it out.

2 · Reply

stockmoe12 Jan. 15 at 1:39 PM

$TSHA before ph3 data they want to tsie it out low price $OCUL .. tsha ph3 data coming q3/q4

0 · Reply

stockmoe12 Jan. 15 at 1:37 PM

$TSHA $OCUL buyout…..

0 · Reply

stockmoe12 Jan. 14 at 6:42 PM

1 · Reply

stockmoe12 Jan. 14 at 4:49 PM

$TSHA slow and steady shorts are getting toasted ….need badly a short squeeze..

0 · Reply

stockmoe12 Jan. 14 at 1:44 AM

$TSHA can we get a short squeeze ..… finviz showing 25% shorts

0 · Reply

stockmoe12 Jan. 13 at 10:57 PM

$TSHA slowly moving and then blast …lets see

0 · Reply

Savon13 Jan. 12 at 2:01 AM

$TSHA https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/flexible-requirements-cell-and-gene-therapies-advance-innovation

1 · Reply

UgoGreg Jan. 10 at 4:11 PM

$TSHA https://youtu.be/ygBN8MilTyc

0 · Reply

stockmoe12 Jan. 9 at 10:50 PM

$TSHA hopefully next week JPM conf and momentum of biotech buyout going to start …..

0 · Reply

stockmoe12 Jan. 9 at 10:49 PM

$TSHA looks like MMs trying to manipulate the price today….

0 · Reply

Dark_Horse_Investments Jan. 9 at 6:20 PM

$TSHA interesting action today ! Today's volume at nearly weekly average on a down day... Just strange, delayed profit taking; any thoughts? With the agreement with FDA by the time Q1-25 ends the BLA data set will be complete, build data 90 days and file mid-late H2-2026 ( expect October ) Adding some more...

1 · Reply

stockmoe12 Jan. 9 at 6:06 PM

$TSHA this is prime for buyout rare disease with peak rev 3.5b and ph3 ongoing .. probability of success 75-85% so should be trading around close to 2b

0 · Reply

stockmoe12 Jan. 9 at 6:05 PM

$TSHA Why someone keeping it down in a up day? may be options sellers … lets squeeze it!!!!!!!

0 · Reply

stockmoe12 Jan. 8 at 11:17 PM

$TSHA Taysha sec filing for 17m total Stock Incentive Plan and Employee Stock Purchase Plan …. I have seen this type of activity before buyout in the past.

0 · Reply

quickaspeter Jan. 8 at 3:07 PM

$TSHA REVEAL clinical trial — PH 3 study testing Rett syndrome gene therapy candidate TSHA-102 — has dosed its first participant, according to Taysha Gene Therapies. https://rettsyndromenews.com/news/reveal-pivotal-trial-rett-gene-therapy-tsha-102-now-underway-recruiting/

0 · Reply

stockmoe12 Jan. 7 at 3:34 AM

$TSHA buyout ?

1 · Reply

stockmoe12 Jan. 7 at 3:34 AM

$TSHA lets go

0 · Reply

stockmoe12 Jan. 7 at 3:32 AM

$TSHA

0 · Reply

quickaspeter Jan. 7 at 1:30 AM

$TSHA 💥🚀💰💰💰 - First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites - Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3, aged 2 to <4 years) in planned BLA submission to support a broad label in patients aged ≥2 years with Rett syndrome - Completion of dosing in REVEAL pivotal trial and ASPIRE trial expected in Q2 2026 - Longer-term safety and efficacy data update from Part A of REVEAL Phase 1/2 trials expected in H1 2026

1 · Reply

stockmoe12 Jan. 6 at 9:17 PM

$TSHA anytime news … like $VTYX

0 · Reply

Market Cap	1.25B
Revenue (ttm)	8.33M
Net Income (ttm)	-89.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,072.03%
Debt to Equity Ratio	0.17

Volume	3,715,500
Avg Vol	3,401,660
Day's Range	N/A - N/A
Shares Out	273.92M
Stochastic %K	6%
Beta	1.02
Analysts	Strong Sell
Price Target	$11.00